RBMX2

Across TCGA pan-cancer cohorts, RBMX2 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated RBMX2 data layer compared with 26 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher RBMX2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated RBMX2 expression acts as an unfavorable survival marker, although some lineages such as HNSC show a favorable association.

CCRCC, HNSC, and LUAD are the cancer types where RBMX2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Quartile	III,IV	0.282	0.783	.010	22	view →
HNSC	OS	Median	II,III,IV	1.000	0.954	.023	6	view →
LUAD	DFS	Median	All	0.496	0.874	.007	5	view →
PDAC	DFS	Quartile	II,III,IV	0.263	0.452	.020	4	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

RBMX2–CCRCC (DFS)

Open the CCRCC breakdown →